Literature DB >> 11014403

Phage therapy: the peculiar kinetics of self-replicating pharmaceuticals.

R J Payne1, D Phil, V A Jansen.   

Abstract

The specter of antibiotic-resistant bacteria has provoked renewed interest in the possible use of bacteriophages to control bacterial infections. We argue that clinical application of phage therapy has been held back by a failure to appreciate the extent to which the pharmacokinetics of self-replicating agents differ from those of normal drugs. For self-replicating pharmaceutical agents, treatment outcome depends critically on various density-dependent thresholds, often with apparently paradoxical consequences. An ability to predict these thresholds and associated critical time points is a necessity if phage therapy is to become clinically practicable.

Entities:  

Mesh:

Year:  2000        PMID: 11014403     DOI: 10.1067/mcp.2000.109520

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  67 in total

1.  Bacteriophage latent-period evolution as a response to resource availability.

Authors:  S T Abedon; T D Herschler; D Stopar
Journal:  Appl Environ Microbiol       Date:  2001-09       Impact factor: 4.792

2.  Overcoming the phage replication threshold: a mathematical model with implications for phage therapy.

Authors:  Laura M Kasman; Alex Kasman; Caroline Westwater; Joseph Dolan; Michael G Schmidt; James S Norris
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

3.  Evidence for a phage proliferation threshold?

Authors:  Robert J H Payne; Vincent A A Jansen
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae.

Authors:  Alex R Hall; Daniel De Vos; Ville-Petri Friman; Jean-Paul Pirnay; Angus Buckling
Journal:  Appl Environ Microbiol       Date:  2012-06-01       Impact factor: 4.792

Review 5.  Pharmacokinetic principles of bacteriophage therapy.

Authors:  Robert J H Payne; Vincent A A Jansen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 6.  Bacteriophage therapy against Enterobacteriaceae.

Authors:  Youqiang Xu; Yong Liu; Yang Liu; Jiangsen Pei; Su Yao; Chi Cheng
Journal:  Virol Sin       Date:  2015-02-03       Impact factor: 4.327

7.  Genome sequencing and analysis of an Escherichia coli phage vB_EcoM-ep3 with a novel lysin, Lysep3.

Authors:  Meng Lv; Shuang Wang; Guangmou Yan; Changjiang Sun; Xin Feng; Jingmin Gu; Wenyu Han; Liancheng Lei
Journal:  Virus Genes       Date:  2015-04-05       Impact factor: 2.332

Review 8.  Bacteriophage secondary infection.

Authors:  Stephen T Abedon
Journal:  Virol Sin       Date:  2015-01-13       Impact factor: 4.327

9.  Targeting antibiotic resistant bacteria with phage reduces bacterial density in an insect host.

Authors:  Lauri Mikonranta; Angus Buckling; Matti Jalasvuori; Ben Raymond
Journal:  Biol Lett       Date:  2019-03-29       Impact factor: 3.703

10.  Phage Therapy - Everything Old is New Again.

Authors:  Andrew M Kropinski
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.